CYP3A4 and metabolic syndrome: On the other hand, a study of > 950,000 patient records from US databases showed that 83% of patients with dyslipidemia used a CYP3A4-metabolised statin and that, of these, 25%-30% also received a CYP3A4 inhibitor [31].